Novo Nordisk Reports Strong CagriSema Weight Loss Results
COPENHAGEN: (News Desk) -Novo Nordisk said its next-generation experimental weight-loss drug CagriSema produced an average weight reduction of 12.4% in a late-stage trial involving people with diabetes, exceeding the results reported for…